KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in Rindopepimut (CDX-110) (6)

Wednesday
Dec212011

NCT01498328

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Sponsors: Celldex Therapeutics
Phase II

Monday
Nov212011

NCT01480479

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Sponsors: Celldex Therapeutics
Phase III

Wednesday
Jan272010

NCT01058850

Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas

Conditions: Brain Cancer, Brain Stem Tumors, Pontine Tumors
Sponsors: Stanford University
Phase I

Tuesday
Mar252008

NCT00643097

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Conditions: Brain and Central Nervous System Tumors
Sponsors: Duke University, National Institute of Neurological Disorders and Stroke
Phase II

Thursday
Feb282008

NCT00626015

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

Conditions: Brain and Central Nervous System Tumors
Sponsors: Duke University, National Cancer Institute (NCI)
Phase I, II

Tuesday
Apr102007

NCT00458601

Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme

Conditions: Malignant Glioma
Sponsors: Celldex Therapeutics
Phase II